Thomas Liu

6.9k total citations · 1 hit paper
19 papers, 784 citations indexed

About

Thomas Liu is a scholar working on Surgery, Economics and Econometrics and Statistics and Probability. According to data from OpenAlex, Thomas Liu has authored 19 papers receiving a total of 784 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Surgery, 7 papers in Economics and Econometrics and 3 papers in Statistics and Probability. Recurrent topics in Thomas Liu's work include Lipoproteins and Cardiovascular Health (9 papers), Pharmaceutical Economics and Policy (6 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Thomas Liu is often cited by papers focused on Lipoproteins and Cardiovascular Health (9 papers), Pharmaceutical Economics and Policy (6 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Thomas Liu collaborates with scholars based in United States, Spain and Australia. Thomas Liu's co-authors include Scott M. Wasserman, Robert C. Scott, Michael J. Koren, Michael A. Bolognese, Lei Lei, Beat Knüsel, Jae B. Kim, Robert P. Giugliano, Marc S. Sabatine and Christiane E. Wobus and has published in prestigious journals such as The Lancet, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Thomas Liu

18 papers receiving 766 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

2012 297 citations Michael J. Koren, Robert C. Scott et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Liu United States	10	513	258	109	102	96	19	784
Chen Huan China	8	246 0.5×	97 0.4×	87 0.8×	72 0.7×	15 0.2×	24	558
Asma Noureen Austria	9	373 0.7×	31 0.1×	135 1.2×	104 1.0×	40 0.4×	18	586
Yiel‐Hea Seo South Korea	12	250 0.5×	14 0.1×	175 1.6×	50 0.5×	35 0.4×	35	742
I. Jensen United States	12	146 0.3×	30 0.1×	123 1.1×	20 0.2×	39 0.4×	45	510
Brandon Swift United States	13	153 0.3×	29 0.1×	17 0.2×	64 0.6×	41 0.4×	23	861
Liangsu Wang United States	14	241 0.5×	21 0.1×	156 1.4×	20 0.2×	31 0.3×	25	731
Andrea Bedynek Germany	10	279 0.5×	7 0.0×	279 2.6×	175 1.7×	57 0.6×	10	713
William M. Sallas United States	10	177 0.3×	17 0.1×	309 2.8×	49 0.5×	11 0.1×	19	758
Marcia Levenstein United States	17	77 0.2×	15 0.1×	62 0.6×	52 0.5×	55 0.6×	27	860
Rajendrakumar H. Jani India	7	63 0.1×	20 0.1×	134 1.2×	56 0.5×	18 0.2×	8	422

Countries citing papers authored by Thomas Liu

Since Specialization

Citations

This map shows the geographic impact of Thomas Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Liu more than expected).

Fields of papers citing papers by Thomas Liu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Liu. The network helps show where Thomas Liu may publish in the future.

Co-authorship network of co-authors of Thomas Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Liu. A scholar is included among the top collaborators of Thomas Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Liu. Thomas Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Gauthier, Timothy P., et al.. (2024). Resources and strategies for learning infectious diseases pharmacotherapy during advanced pharmacy practice experiences and pharmacy residency. American Journal of Health-System Pharmacy. 82(4). 228–234. 1 indexed citations

Liu, Thomas, et al.. (2022). Bleeding gums due to immune thrombocytopenic purpura. Journal of Osteopathic Medicine. 122(4). 217–218. 1 indexed citations

Liu, Thomas, et al.. (2021). Man with ear injury. SHILAP Revista de lepidopterología. 2(6). e12594–e12594. 1 indexed citations

Wasserman, Scott M., Marc S. Sabatine, Michael J. Koren, et al.. (2018). Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals. Journal of Cardiovascular Pharmacology and Therapeutics. 23(5). 423–432. 7 indexed citations

Desai, Nihar R., Robert P. Giugliano, Scott M. Wasserman, et al.. (2017). Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab. JAMA Cardiology. 2(5). 556–556. 23 indexed citations

Stein, Evan A., Ransi Somaratne, C. Stephen Djedjos, et al.. (2016). PCSK9 INHIBITION-MEDIATED REDUCTION IN TRIGLYCERIDE WITH EVOLOCUMAB IS RELATED TO BASELINE TRIGLYCERIDE LEVELS: AN ANALYSIS FROM 1791 PATIENTS. Journal of the American College of Cardiology. 67(13). 1866–1866. 2 indexed citations

Koren, Michael J., Robert P. Giugliano, Frederick J. Raal, et al.. (2015). TWO YEAR ANALYSIS OF THE SAFETY AND TOLERABILITY OF EVOLOCUMAB: THE OSLER-1 STUDY. Journal of the American College of Cardiology. 65(10). A1364–A1364. 1 indexed citations

Desai, Nihar R., Robert P. Giugliano, Scott M. Wasserman, et al.. (2014). Abstract 16196: Impact of Baseline PCSK9 Levels on the Efficacy of Evolocumab, a Monoclonal Antibody Against PCSK9. Circulation. 130(suppl_2). 1 indexed citations

Gonzalez-Hernandez, Mariam B., Thomas Liu, Jennifer Stencel-Baerenwald, et al.. (2014). Efficient Norovirus and Reovirus Replication in the Mouse Intestine Requires Microfold (M) Cells. Journal of Virology. 88(12). 6934–6943. 87 indexed citations

10.

Wasserman, Scott M., Michael J. Koren, Robert P. Giugliano, et al.. (2014). Abstract 16270: Evaluation of the Relationship Between Evolocumab 140 mg Every Two Weeks and 420 mg Monthly Dosing Regimens. 130. 2 indexed citations

11.

Desai, Nihar R., Robert P. Giugliano, Jing Zhou, et al.. (2013). AMG 145, a Monoclonal Antibody Against PCSK9, Facilitates Achievement of National Cholesterol Education Program–Adult Treatment Panel III Low-Density Lipoprotein Cholesterol Goals Among High-Risk Patients. Journal of the American College of Cardiology. 63(5). 430–433. 42 indexed citations

12.

Gonzalez-Hernandez, Mariam B., et al.. (2013). Murine Norovirus Transcytosis across anIn VitroPolarized Murine Intestinal Epithelial Monolayer Is Mediated by M-Like Cells. Journal of Virology. 87(23). 12685–12693. 35 indexed citations

13.

Chen, Ming‐Hui, et al.. (2013). Bayesian sequential meta‐analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program. Statistics in Medicine. 33(9). 1600–1618. 15 indexed citations

14.

Koren, Michael J., Robert P. Giugliano, Frederick J. Raal, et al.. (2013). Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia. Circulation. 129(2). 234–243. 176 indexed citations

15.

Raal, Frederick J., Robert P. Giugliano, Michael J. Koren, et al.. (2013). Efficacy and Safety of AMG 145, a Fully Human Monoclonal Antibody to PCSK9: Data from Four Phase 2 Studies in Over 1200 Patients. Journal of clinical lipidology. 7(3). 278–278. 1 indexed citations

16.

Koren, Michael J., Robert C. Scott, Jae B. Kim, et al.. (2012). Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. The Lancet. 380(9858). 1995–2006. 297 indexed citations breakdown →

17.

Ibrahim, Joseph G., Ming‐Hui Chen, H. Amy Xia, & Thomas Liu. (2011). Bayesian Meta‐Experimental Design: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. Biometrics. 68(2). 578–586. 39 indexed citations

18.

Kong, Lan, Gary G. Koch, Thomas Liu, & Huei Wang. (2005). Performance of some multiple testing procedures to compare three doses of a test drug and placebo. Pharmaceutical Statistics. 4(1). 25–35. 10 indexed citations

19.

Holt, Peter R., et al.. (1996). Regional distribution of carcinogen‐induced colonic neoplasia in the rat. Nutrition and Cancer. 25(2). 129–135. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact